[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 18, Issue 3 (Autumn 2021) ::
Sci J Iran Blood Transfus Organ 2021, 18(3): 161-170 Back to browse issues page
The effect of sCD40L derived from platelet concentrate on cell survival and activation of Daudi cells
A. Nemati, F. Yari , M. Mohammadipour, N. Rezaei
Keywords: Platelets, Survival, B-Lymphocytes
ت
Full-Text [PDF 503 kb]   (86 Downloads)     |   Abstract (HTML)  (303 Views)
Type of Study: Research | Subject: Imunology
Published: 2021/10/2
Full-Text:   (147 Views)
    References:
 
 
  1. Michel NA, Zirlik A, Wolf D. CD40L and its receptors in atherothrombosis-an update. Front Cardiovasc Med 2017; 4: 40.
  2. Ludewig B, Henn V, Schröder JM, Graf D, Kroczek RA. Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur J  Immunol 1996;  26(12): 3137-43.
  3. Graf D, Müller S, Korthäuer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur  J Immunol 1995; 25(6): 1749-54.
  4. Tang TT, Cheng X, Truong B, Sun L, Yang X, Wang H. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol  Ther 2021; 219: 107709.
  5. Elgueta R, Benson MJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229(1): 152-72.
  6. van Kooten C, Banchereau J. CD40- CD40 ligand. J Leukoc Biol 2000; 67(1): 2-17.
  7. Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev 2019; 141: 92-103.
  8. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16(1): 111-35.
  9. Cognasse F, Lafarge S, Chavarin P, Acquart S, Garraud O. Lipopolysaccharide induces sCD40L release through human platelets TLR4, but not TLR2 and TLR9. Intensive Care Med 2007; 33(2): 382-4.
  10. Corash L, Cognasse F, Osselaer JC, Messe N, Van Hooydonk M, Garraud O. Cytokines in platelet components associated with acute transfusion reactions: The role of sCd40L. Blood 2006; (108)11: 952.
  11. Nomura S, Fujita S, Nakanishi T, Yokoi T, Shimamoto K, Miyamoto R, et al. Platelet-derived microparticles cause CD154-dependent activation of dendritic cells. Platelets 2012; 23(1): 81-2.
  12. Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood 2008; 111(10): 5028-36.
  13. Elzey BD, Ratliff TL, Sowa JM, Crist SA. Platelet CD40L at the interface of adaptive immunity. Thromb Res 2011; 127(3): 180-3.
  14. Seong R, Clayberger CA, Krensky AM, Parnes JR. Rescue of Daudi cell HLA expression by transfection of the mouse beta 2-microglobulin gene. J Exp Med 1988; 167(2): 288-99.
  15. Rosa F, Fellous M, Dron M, Tovey M, Revel M. Presence of an abnormal β 2-microglobulin mRNA in Daudi cells: induction by interferon. Immunogenetics 1983; 17(2): 125-31.
  16. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005; 17(3): 275-81.
  17. Aloui C, Prigent A, Sut C, Tariket S, Hamzeh-
    Cognasse H, Pozzetto B, et al. The signaling role of CD40 ligand in platelet biology and in platelet component transfusion. Int J Mol Sci  2014; 15(12): 22342-64.
  18. Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Throm Haemost 2009; 102(2): 206-14.
  19. Banchereau J, Rousset F. Growing human B lymphocytes in the CD40 system. Nature 1991; 353(6345): 678-9.
  20. Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato TA, et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992; 176(6): 1543-50.
  21. Cognasse F, Hamzeh-Cognasse H, Lafarge S, Chavarin P, Cogné M, Richard Y, et al. Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol 2007; 35(9): 1376-87.
  22. Yari F, Motefaker M, Nikougoftar M, Khayati Z. Interaction of platelet-derived microparticles with a human B-lymphoblast cell line: A clue for the immunologic function of the microparticles. Transfus Med Hemother 2018; 45(1): 55-61.
 

 
 
 
Sci J Iran Blood Transfus Organ 2021;18 (3): 161-170
Original Article
 
 
 
 
 


The effect of sCD40L derived from platelet concentrate
on cell survival and activation of Daudi cells
 
Nemati A.1, Yari F.1, Mohammadipour M.1, Rezaei N.2
 
 
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
 
 
 
Abstract
Background and Objectives
Previous studies have suggested an association between the importance of CD40L and B lymphocytes. CD40L derived from platelets plays an important role in the activation of B lymphocytes and humoral immunity. The aim of the present study was to investigate the effect of purified CD40L from platelet product on the survival and activation of Daudi cells as an available surrogate cell line for peripheral blood B lymphocytes.
 
Materials and Methods
In an experimental study, Purified CD40L from platelet product was exposed to Daudi cells at concentrations of 500 and 1000 ng/mL. After 48 and 72 hours of exposure, cell survival was studied with MTT assay and CD27 expression with flow cytometry. SPSS software and Independent T Test and Mann-Whitney tests were used for statistical analysis.
 
Results
The results showed a significant increase in cell survival at 48 hours after exposure to 1000 ng/mL of CD40L with p = 0.04 (0.61 ± 0.41) compared to the control group with the mean of 0.30 ± 0.15 while in 500 ng/mL with (0.58 ± 0.35), it was insignificant. CD27 expression did not show a significant increase in all concentrations.
 
Conclusions 
Soluble CD40L has been effective in the survival of Daudi cells at higher concentrations. A slight increase in CD27 as one of the activation markers of B lymphocytes suggests the need to provide more appropriate conditions such as the use of cytokines in the cell culture medium.
 
Key words: Platelets, Survival, B-Lymphocytes
 
 
 
 
 
 
 
 
Received:  28 Oct 2020
Accepted: 23 Dec 2020
 
 

Correspondence: Yari F., PhD of Immunology. Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052237; Fax: (+9821) 88601555
E-mail: f.yari@ibto.ir
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nemati A, Yari F, Mohammadipour M, Rezaei N. The effect of sCD40L derived from platelet concentrate on cell survival and activation of Daudi cells. Sci J Iran Blood Transfus Organ. 2021; 18 (3) :161-170
URL: http://bloodjournal.ir/article-1-1378-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 18, Issue 3 (Autumn 2021) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.05 seconds with 31 queries by YEKTAWEB 4374